What does Actavis get in $66bn Allergan buy?

When Actavis closes its $66bn acquisition of Allergan, the generic drug specialist and growing brand-name medicine marketer will grow in international markets and strengthen or add products in certain disease areas (scripintelligence.com, 18 November 2014).

When Actavis closes its $66bn acquisition of Allergan, the generic drug specialist and growing brand-name medicine marketer will grow in international markets and strengthen or add products in certain disease areas (scripintelligence.com, 18 November 2014).

Actavis will expand its international business base in Canada, Europe, Southeast Asia and other emerging markets, such as China, India,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category